Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

IOTA Simple Rules

IOTA Simple Rules

International Ovarian Tumor Analysis

Benign Features (B-Rules)
Malignant Features (M-Rules)

IOTA Conclusion

INCONCLUSIVE / UNCLASSIFIED

Simple Rules can classify ~75% of masses. Masses that don't fit (neither or both types) should be analyzed using IOTA ADNEX / Specialist assessment.

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Primary Clinical Uses

Sonographic characterization of adnexal/ovarian masses
Triaging surgical referrals (general gynecology vs. gynecologic oncology)
Standardizing global ultrasound terminology regarding ovarian cysts

Why it Exists

Prior to IOTA, radiologists used highly subjective terminology ("complex", "worrisome", "thickened") that caused massive over-operation by oncologists for universally benign cysts, and accidental rupture of malignant cysts by generalists.

How it Works

B-Features (Benign)

B1: Unilocular
B2: Presence of solid components, but largest is < 7 mm
B3: Presence of acoustic shadows (classic for dermoids)
B4: Smooth multilocular tumor with largest diameter < 100 mm
B5: No blood flow on Doppler (Color Score 1)

M-Features (Malignant)

M1: Irregular solid tumor
M2: Presence of ascites
M3: At least 4 papillary structures
M4: Irregular multilocular solid tumor with largest diameter ≥ 100 mm
M5: Very strong blood flow on Doppler (Color Score 4)

Clinical Pearls

The Diagnostic Algorithm

Rule 1 (Benign): Must have at least one B-feature AND zero M-features.
Rule 2 (Malignant): Must have at least one M-feature AND zero B-features.
Rule 3 (Inconclusive): If it has both B and M features, or NEITHER, the rules do not apply.

Inconclusive Masses

The Simple Rules are highly accurate (~90-95%) but only applicable to about 76% of all adnexal masses.
For the ~24% that are inconclusive, you MUST defer to an expert ultrasound examiner, an MRI, or apply advanced mathematical models (like IOTA ADNEX).

Next Steps

Clinical Triage

01
Benign: Safe for conservative management, surveillance, or cystectomy/oophorectomy by a general gynecologist depending on symptoms.
02
Malignant: Absolute requirement for referral to a trained Gynecologic Oncologist. Attempting surgery by a generalist risks capsule rupture, upgrading the staging and ruining survival odds.
03
Inconclusive: Escalate diagnostic imaging (Pelvic MRI with contrast) or utilize the continuous ADNEX model.

The Evidence

Phase 2 IOTA Study

Simple ultrasound-based rules for the diagnosis of ovarian cancer.

Timmerman D et al. • Ultrasound Obstet Gynecol.. 2008;Developed the 10 rules using 1938 women, proving a 95% sensitivity and 91% specificity for the masses where the rules could be conclusively applied.

Origins & History

The IOTA Group

The International Ovarian Tumor Analysis (IOTA) consortium revolutionized ultrasound. Rather than relying on tumor markers like CA-125 (which has catastrophic false positive rates in premenopausal women due to endometriosis), they forced objective morphology to dictate risk.

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

WHO NewsJul 20, 2026
Road deaths fall by 21% globally but stronger action is needed to save lives

Clinical Context

We think this might be relevant to the clinical guidance for IOTA Simple Rules.

WHO NewsJul 15, 2026
Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO

Clinical Context

We think this might be relevant to the clinical guidance for IOTA Simple Rules.

WHO NewsJun 15, 2026
Open letter to leaders of G7, G20, BRICS and all nations on finalizing the WHO Pandemic Agreement’s Pathogen Access and Benefit Sharing annex

Clinical Context

We think this might be relevant to the clinical guidance for IOTA Simple Rules.